Skip to main content
KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc. — Investor Relations & Filings

Ticker · KRMD ISIN · US7599101026 US Manufacturing
Filings indexed 922 across all filing types
Latest filing 2024-03-15 Director's Dealing
Country US United States of America
Listing US KRMD

About KORU Medical Systems, Inc.

https://www.korumedical.com/

KORU Medical Systems is a medical technology company that designs, develops, manufactures, and commercializes subcutaneous infusion solutions. The company's primary offering is the Freedom™ Infusion System, which includes syringe infusion pumps and related accessories. These systems are engineered for the delivery of large-volume subcutaneous drugs, such as immunoglobulins, to treat patients with chronic illnesses. KORU Medical Systems focuses on providing patient-centric solutions that facilitate safe and effective home-based infusion therapy, aiming to enhance patient quality of life by offering greater freedom and flexibility in treatment management.

Recent filings

Filing Released Lang Actions
FORM 4 FOR 03-13-2024
Director's Dealing
2024-03-15 English
FORM 8-K CURRENT REPORT FOR 03-08-2024
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 8, 2024, by KORU Medical Systems, Inc. It includes disclosures about entering into a material definitive agreement (a loan and security agreement), a press release announcing financial results for the fourth quarter and year ended December 31, 2023, and financial guidance, as well as a conference call announcement. The document also references exhibits including the loan agreement and a stock purchase warrant. The content primarily focuses on financing activities (loan agreement details) and financial results announcements. The presence of detailed loan terms and credit facility information indicates a capital/financing update. The financial results announcement and conference call are mentioned but the document itself is not the earnings release or call transcript; it is a regulatory filing reporting these events. Given the detailed loan agreement and financing terms, the primary classification is Capital/Financing Update (CAP). The document is not an earnings release (ER) or call transcript (CT) itself, nor is it an annual or quarterly report. Therefore, the best fit is CAP with high confidence.
2024-03-13 English
FORM 10-K ANNUAL REPORT FOR 12-31-2023
Annual Report FY 2023
2024-03-13 English
4
Director's Dealing
2024-02-16 English
SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP
Major Shareholding Notification
2024-02-14 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.